Anti-V. vulnificus RtxA-1 protein Recombinant Antibody (21RA) (MRO-141MZ) (CAT#: MRO-141MZ)

Figure 1 Prophylactic efficacies of anti-RtxA1-C MAbs.

Survival of mice treated with anti-RtxA1-C MAbs. A single dose of purified MAbs (1 mg) or ascitic fluid (200 μl) was passively transferred to 8-week-old CD1 mice via the intraperitoneal (i.p.) route, 4.5 h prior to i.p. infection with 1 × 10⁶ or 8 × 10⁶.

Monoclonal Antibodies against Vibrio vulnificus RtxA1 Elicit Protective Immunity through Distinct Mechanisms

Figure 2 Prophylactic efficacies of anti-RtxA2-C MAbs.

Therapeutic effects after intraperitoneal (i.p.) and subcutaneous (s.c.) infections. (A) At 1 h postinfection i.p. with 1 × 10⁶ CFU of V. vulnificus, 8-week-old CD1 mice were passively transferred a single dose of purified MAbs (0.5 or 1 mg), ascitic fluid (200 μl), or saline (PBS) i.p. As shown in Table 2, 21RA, 24RA, and 47RA exhibited significant therapeutic efficacies (P ≤ 0.0008), but 13RA, 45RA, and 50RA did not. Survival curves were constructed using data from more than two independent experiments, each with five to six animals.

Monoclonal Antibodies against Vibrio vulnificus RtxA1 Elicit Protective Immunity through Distinct Mechanisms

Figure 3 Immunoreactivity and cross-protection efficiency of anti-RtxA1-C MAbs against different V. vulnificus strains.

Monoclonal Antibodies against Vibrio vulnificus RtxA1 Elicit Protective Immunity through Distinct Mechanisms